List of Tables
Table 1. Global New Molecular Entities (NME) Drugs Market Value by Type (US$ Million), 2025 vs 2032
Table 2. Global New Molecular Entities (NME) Drugs Market Value by Administration Route (US$ Million), 2025 vs 2032
Table 3. Global New Molecular Entities (NME) Drugs Market Value by Action Mechanism (US$ Million), 2025 vs 2032
Table 4. Global New Molecular Entities (NME) Drugs Market Value by Application (US$ Million), 2025 vs 2032
Table 5. Global New Molecular Entities (NME) Drugs Market Competitive Situation by Manufacturers in 2025
Table 6. Global New Molecular Entities (NME) Drugs Sales (M Units) of Key Manufacturers (2021–2026)
Table 7. Global New Molecular Entities (NME) Drugs Sales Market Share by Manufacturers (2021–2026)
Table 8. Global New Molecular Entities (NME) Drugs Revenue (US$ Million) by Manufacturers (2021–2026)
Table 9. Global New Molecular Entities (NME) Drugs Revenue Share by Manufacturers (2021–2026)
Table 10. Global Market New Molecular Entities (NME) Drugs Average Price (US$/Unit) of Key Manufacturers (2021–2026)
Table 11. Global Key Players of New Molecular Entities (NME) Drugs, Industry Ranking, 2023 vs 2024 vs 2025
Table 12. Global Key Manufacturers of New Molecular Entities (NME) Drugs, Manufacturing Sites and Headquarters
Table 13. Global Key Manufacturers of New Molecular Entities (NME) Drugs, Product Types and Applications
Table 14. Global Key Manufacturers of New Molecular Entities (NME) Drugs, Date of Entry into the Industry
Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 16. Global New Molecular Entities (NME) Drugs Companies by Tier (Tier 1, Tier 2, Tier 3), based on New Molecular Entities (NME) Drugs Revenue, 2025
Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 18. Global New Molecular Entities (NME) Drugs Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 19. Global New Molecular Entities (NME) Drugs Sales by Region (M Units), 2021–2026
Table 20. Global New Molecular Entities (NME) Drugs Sales Market Share by Region (2021–2026)
Table 21. Global New Molecular Entities (NME) Drugs Sales by Region (M Units), 2027–2032
Table 22. Global New Molecular Entities (NME) Drugs Sales Market Share by Region (2027–2032)
Table 23. Global New Molecular Entities (NME) Drugs Revenue by Region (US$ Million), 2021–2026
Table 24. Global New Molecular Entities (NME) Drugs Revenue Market Share by Region (2021–2026)
Table 25. Global New Molecular Entities (NME) Drugs Revenue by Region (US$ Million), 2027–2032
Table 26. Global New Molecular Entities (NME) Drugs Revenue Market Share by Region (2027–2032)
Table 27. North America New Molecular Entities (NME) Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 28. North America New Molecular Entities (NME) Drugs Sales by Country (M Units), 2021–2026
Table 29. North America New Molecular Entities (NME) Drugs Sales by Country (M Units), 2027–2032
Table 30. North America New Molecular Entities (NME) Drugs Revenue by Country (US$ Million), 2021–2026
Table 31. North America New Molecular Entities (NME) Drugs Revenue by Country (US$ Million), 2027–2032
Table 32. Europe New Molecular Entities (NME) Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 33. Europe New Molecular Entities (NME) Drugs Sales by Country (M Units), 2021–2026
Table 34. Europe New Molecular Entities (NME) Drugs Sales by Country (M Units), 2027–2032
Table 35. Europe New Molecular Entities (NME) Drugs Revenue by Country (US$ Million), 2021–2026
Table 36. Europe New Molecular Entities (NME) Drugs Revenue by Country (US$ Million), 2027–2032
Table 37. Asia Pacific New Molecular Entities (NME) Drugs Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 38. Asia Pacific New Molecular Entities (NME) Drugs Sales by Region (M Units), 2021–2026
Table 39. Asia Pacific New Molecular Entities (NME) Drugs Sales by Region (M Units), 2027–2032
Table 40. Asia Pacific New Molecular Entities (NME) Drugs Revenue by Region (US$ Million), 2021–2026
Table 41. Asia Pacific New Molecular Entities (NME) Drugs Revenue by Region (US$ Million), 2027–2032
Table 42. Latin America New Molecular Entities (NME) Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 43. Latin America New Molecular Entities (NME) Drugs Sales by Country (M Units), 2021–2026
Table 44. Latin America New Molecular Entities (NME) Drugs Sales by Country (M Units), 2027–2032
Table 45. Latin America New Molecular Entities (NME) Drugs Revenue by Country (US$ Million), 2021–2026
Table 46. Latin America New Molecular Entities (NME) Drugs Revenue by Country (US$ Million), 2027–2032
Table 47. Middle East and Africa New Molecular Entities (NME) Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 48. Middle East and Africa New Molecular Entities (NME) Drugs Sales by Country (M Units), 2021–2026
Table 49. Middle East and Africa New Molecular Entities (NME) Drugs Sales by Country (M Units), 2027–2032
Table 50. Middle East and Africa New Molecular Entities (NME) Drugs Revenue by Country (US$ Million), 2021–2026
Table 51. Middle East and Africa New Molecular Entities (NME) Drugs Revenue by Country (US$ Million), 2027–2032
Table 52. Global New Molecular Entities (NME) Drugs Sales (M Units) by Type (2021–2026)
Table 53. Global New Molecular Entities (NME) Drugs Sales (M Units) by Type (2027–2032)
Table 54. Global New Molecular Entities (NME) Drugs Sales Market Share by Type (2021–2026)
Table 55. Global New Molecular Entities (NME) Drugs Sales Market Share by Type (2027–2032)
Table 56. Global New Molecular Entities (NME) Drugs Revenue (US$ Million) by Type (2021–2026)
Table 57. Global New Molecular Entities (NME) Drugs Revenue (US$ Million) by Type (2027–2032)
Table 58. Global New Molecular Entities (NME) Drugs Revenue Market Share by Type (2021–2026)
Table 59. Global New Molecular Entities (NME) Drugs Revenue Market Share by Type (2027–2032)
Table 60. Global New Molecular Entities (NME) Drugs Price (US$/Unit) by Type (2021–2026)
Table 61. Global New Molecular Entities (NME) Drugs Price (US$/Unit) by Type (2027–2032)
Table 62. Global New Molecular Entities (NME) Drugs Sales (M Units) by Application (2021–2026)
Table 63. Global New Molecular Entities (NME) Drugs Sales (M Units) by Application (2027–2032)
Table 64. Global New Molecular Entities (NME) Drugs Sales Market Share by Application (2021–2026)
Table 65. Global New Molecular Entities (NME) Drugs Sales Market Share by Application (2027–2032)
Table 66. Global New Molecular Entities (NME) Drugs Revenue (US$ Million) by Application (2021–2026)
Table 67. Global New Molecular Entities (NME) Drugs Revenue (US$ Million) by Application (2027–2032)
Table 68. Global New Molecular Entities (NME) Drugs Revenue Market Share by Application (2021–2026)
Table 69. Global New Molecular Entities (NME) Drugs Revenue Market Share by Application (2027–2032)
Table 70. Global New Molecular Entities (NME) Drugs Price (US$/Unit) by Application (2021–2026)
Table 71. Global New Molecular Entities (NME) Drugs Price (US$/Unit) by Application (2027–2032)
Table 72. Roche Company Information
Table 73. Roche Description and Business Overview
Table 74. Roche New Molecular Entities (NME) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 75. Roche New Molecular Entities (NME) Drugs Product
Table 76. Roche Recent Developments/Updates
Table 77. Novartis Company Information
Table 78. Novartis Description and Business Overview
Table 79. Novartis New Molecular Entities (NME) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 80. Novartis New Molecular Entities (NME) Drugs Product
Table 81. Novartis Recent Developments/Updates
Table 82. Merck Company Information
Table 83. Merck Description and Business Overview
Table 84. Merck New Molecular Entities (NME) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 85. Merck New Molecular Entities (NME) Drugs Product
Table 86. Merck Recent Developments/Updates
Table 87. Pfizer Company Information
Table 88. Pfizer Description and Business Overview
Table 89. Pfizer New Molecular Entities (NME) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 90. Pfizer New Molecular Entities (NME) Drugs Product
Table 91. Pfizer Recent Developments/Updates
Table 92. AstraZeneca Company Information
Table 93. AstraZeneca Description and Business Overview
Table 94. AstraZeneca New Molecular Entities (NME) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 95. AstraZeneca New Molecular Entities (NME) Drugs Product
Table 96. AstraZeneca Recent Developments/Updates
Table 97. Johnson & Johnson Company Information
Table 98. Johnson & Johnson Description and Business Overview
Table 99. Johnson & Johnson New Molecular Entities (NME) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 100. Johnson & Johnson New Molecular Entities (NME) Drugs Product
Table 101. Johnson & Johnson Recent Developments/Updates
Table 102. Bristol Myers Squibb Company Information
Table 103. Bristol Myers Squibb Description and Business Overview
Table 104. Bristol Myers Squibb New Molecular Entities (NME) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 105. Bristol Myers Squibb New Molecular Entities (NME) Drugs Product
Table 106. Bristol Myers Squibb Recent Developments/Updates
Table 107. Bayer Company Information
Table 108. Bayer Description and Business Overview
Table 109. Bayer New Molecular Entities (NME) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 110. Bayer New Molecular Entities (NME) Drugs Product
Table 111. Bayer Recent Developments/Updates
Table 112. GSK Company Information
Table 113. GSK Description and Business Overview
Table 114. GSK New Molecular Entities (NME) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 115. GSK New Molecular Entities (NME) Drugs Product
Table 116. GSK Recent Developments/Updates
Table 117. Daiichi Sankyo Company Information
Table 118. Daiichi Sankyo Description and Business Overview
Table 119. Daiichi Sankyo New Molecular Entities (NME) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 120. Daiichi Sankyo New Molecular Entities (NME) Drugs Product
Table 121. Daiichi Sankyo Recent Developments/Updates
Table 122. Amgen Company Information
Table 123. Amgen Description and Business Overview
Table 124. Amgen New Molecular Entities (NME) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 125. Amgen New Molecular Entities (NME) Drugs Product
Table 126. Amgen Recent Developments/Updates
Table 127. Eli Lilly and Company Company Information
Table 128. Eli Lilly and Company Description and Business Overview
Table 129. Eli Lilly and Company New Molecular Entities (NME) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 130. Eli Lilly and Company New Molecular Entities (NME) Drugs Product
Table 131. Eli Lilly and Company Recent Developments/Updates
Table 132. AbbVie Company Information
Table 133. AbbVie Description and Business Overview
Table 134. AbbVie New Molecular Entities (NME) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 135. AbbVie New Molecular Entities (NME) Drugs Product
Table 136. AbbVie Recent Developments/Updates
Table 137. Sanofi Company Information
Table 138. Sanofi Description and Business Overview
Table 139. Sanofi New Molecular Entities (NME) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 140. Sanofi New Molecular Entities (NME) Drugs Product
Table 141. Sanofi Recent Developments/Updates
Table 142. Takeda Company Information
Table 143. Takeda Description and Business Overview
Table 144. Takeda New Molecular Entities (NME) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 145. Takeda New Molecular Entities (NME) Drugs Product
Table 146. Takeda Recent Developments/Updates
Table 147. Boehringer Ingelheim Company Information
Table 148. Boehringer Ingelheim Description and Business Overview
Table 149. Boehringer Ingelheim New Molecular Entities (NME) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 150. Boehringer Ingelheim New Molecular Entities (NME) Drugs Product
Table 151. Boehringer Ingelheim Recent Developments/Updates
Table 152. Beigene, Ltd. Company Information
Table 153. Beigene, Ltd. Description and Business Overview
Table 154. Beigene, Ltd. New Molecular Entities (NME) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 155. Beigene, Ltd. New Molecular Entities (NME) Drugs Product
Table 156. Beigene, Ltd. Recent Developments/Updates
Table 157. Jiangsu Hengrui Medicine Company Information
Table 158. Jiangsu Hengrui Medicine Description and Business Overview
Table 159. Jiangsu Hengrui Medicine New Molecular Entities (NME) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 160. Jiangsu Hengrui Medicine New Molecular Entities (NME) Drugs Product
Table 161. Jiangsu Hengrui Medicine Recent Developments/Updates
Table 162. INNOVENT BIOLOGICS(SUZHOU) Company Information
Table 163. INNOVENT BIOLOGICS(SUZHOU) Description and Business Overview
Table 164. INNOVENT BIOLOGICS(SUZHOU) New Molecular Entities (NME) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 165. INNOVENT BIOLOGICS(SUZHOU) New Molecular Entities (NME) Drugs Product
Table 166. INNOVENT BIOLOGICS(SUZHOU) Recent Developments/Updates
Table 167. Betta Pharmaceuticals Company Information
Table 168. Betta Pharmaceuticals Description and Business Overview
Table 169. Betta Pharmaceuticals New Molecular Entities (NME) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 170. Betta Pharmaceuticals New Molecular Entities (NME) Drugs Product
Table 171. Betta Pharmaceuticals Recent Developments/Updates
Table 172. Remegen Co.,Ltd. Company Information
Table 173. Remegen Co.,Ltd. Description and Business Overview
Table 174. Remegen Co.,Ltd. New Molecular Entities (NME) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 175. Remegen Co.,Ltd. New Molecular Entities (NME) Drugs Product
Table 176. Remegen Co.,Ltd. Recent Developments/Updates
Table 177. Shanghai Allist Pharmaceuticals Company Information
Table 178. Shanghai Allist Pharmaceuticals Description and Business Overview
Table 179. Shanghai Allist Pharmaceuticals New Molecular Entities (NME) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 180. Shanghai Allist Pharmaceuticals New Molecular Entities (NME) Drugs Product
Table 181. Shanghai Allist Pharmaceuticals Recent Developments/Updates
Table 182. Innocare Company Information
Table 183. Innocare Description and Business Overview
Table 184. Innocare New Molecular Entities (NME) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 185. Innocare New Molecular Entities (NME) Drugs Product
Table 186. Innocare Recent Developments/Updates
Table 187. Huiyu Pharmaceuticals Company Information
Table 188. Huiyu Pharmaceuticals Description and Business Overview
Table 189. Huiyu Pharmaceuticals New Molecular Entities (NME) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 190. Huiyu Pharmaceuticals New Molecular Entities (NME) Drugs Product
Table 191. Huiyu Pharmaceuticals Recent Developments/Updates
Table 192. Key Raw Materials Lists
Table 193. Raw Materials Key Suppliers Lists
Table 194. New Molecular Entities (NME) Drugs Distributors List
Table 195. New Molecular Entities (NME) Drugs Customers List
Table 196. New Molecular Entities (NME) Drugs Market Trends
Table 197. New Molecular Entities (NME) Drugs Market Drivers
Table 198. New Molecular Entities (NME) Drugs Market Challenges
Table 199. New Molecular Entities (NME) Drugs Market Restraints
Table 200. Research Programs/Design for This Report
Table 201. Key Data Information from Secondary Sources
Table 202. Key Data Information from Primary Sources
Table 203. Authors List of This Report
List of Figures
Figure 1. Product Picture of New Molecular Entities (NME) Drugs
Figure 2. Global New Molecular Entities (NME) Drugs Market Value by Type (US$ Million), 2021–2032
Figure 3. Global New Molecular Entities (NME) Drugs Market Share by Type: 2025 & 2032
Figure 4. Small Molecules Product Picture
Figure 5. Monoclonal Antibodies Product Picture
Figure 6. ADCs Product Picture
Figure 7. Others Product Picture
Figure 8. Global New Molecular Entities (NME) Drugs Market Value by Administration Route (US$ Million), 2021–2032
Figure 9. Global New Molecular Entities (NME) Drugs Market Share by Administration Route: 2025 vs 2032
Figure 10. Oral Drugs Product Picture
Figure 11. Injectable Drugs Product Picture
Figure 12. Others Product Picture
Figure 13. Global New Molecular Entities (NME) Drugs Market Value by Action Mechanism (US$ Million), 2021–2032
Figure 14. Global New Molecular Entities (NME) Drugs Market Share by Action Mechanism: 2025 vs 2032
Figure 15. Receptor Agonists Product Picture
Figure 16. Enzyme Inhibitors Product Picture
Figure 17. Others Product Picture
Figure 18. Global New Molecular Entities (NME) Drugs Market Value by Application (US$ Million), 2021–2032
Figure 19. Global New Molecular Entities (NME) Drugs Market Share by Application: 2025 & 2032
Figure 20. Cancer Diseases
Figure 21. Immune Diseases
Figure 22. Cardiovascular Diseases
Figure 23. Others
Figure 24. Global New Molecular Entities (NME) Drugs Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 25. Global New Molecular Entities (NME) Drugs Market Size (US$ Million), 2021–2032
Figure 26. Global New Molecular Entities (NME) Drugs Sales (M Units), 2021–2032
Figure 27. Global New Molecular Entities (NME) Drugs Average Price (US$/Unit), 2021–2032
Figure 28. New Molecular Entities (NME) Drugs Report Years Considered
Figure 29. New Molecular Entities (NME) Drugs Sales Share by Manufacturers in 2025
Figure 30. Global New Molecular Entities (NME) Drugs Revenue Share by Manufacturers in 2025
Figure 31. Top 5 and Top 10 Global New Molecular Entities (NME) Drugs Players: Market Share by Revenue in New Molecular Entities (NME) Drugs in 2025
Figure 32. New Molecular Entities (NME) Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 33. Global New Molecular Entities (NME) Drugs Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Figure 34. North America New Molecular Entities (NME) Drugs Sales Market Share by Country (2021–2032)
Figure 35. North America New Molecular Entities (NME) Drugs Revenue Market Share by Country (2021–2032)
Figure 36. United States New Molecular Entities (NME) Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 37. Canada New Molecular Entities (NME) Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 38. Europe New Molecular Entities (NME) Drugs Sales Market Share by Country (2021–2032)
Figure 39. Europe New Molecular Entities (NME) Drugs Revenue Market Share by Country (2021–2032)
Figure 40. Germany New Molecular Entities (NME) Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 41. France New Molecular Entities (NME) Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 42. U.K. New Molecular Entities (NME) Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 43. Italy New Molecular Entities (NME) Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 44. Russia New Molecular Entities (NME) Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 45. Asia Pacific New Molecular Entities (NME) Drugs Sales Market Share by Region (2021–2032)
Figure 46. Asia Pacific New Molecular Entities (NME) Drugs Revenue Market Share by Region (2021–2032)
Figure 47. China New Molecular Entities (NME) Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 48. Japan New Molecular Entities (NME) Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 49. South Korea New Molecular Entities (NME) Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 50. India New Molecular Entities (NME) Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 51. Australia New Molecular Entities (NME) Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 52. China Taiwan New Molecular Entities (NME) Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 53. Southeast Asia New Molecular Entities (NME) Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 54. Latin America New Molecular Entities (NME) Drugs Sales Market Share by Country (2021–2032)
Figure 55. Latin America New Molecular Entities (NME) Drugs Revenue Market Share by Country (2021–2032)
Figure 56. Mexico New Molecular Entities (NME) Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 57. Brazil New Molecular Entities (NME) Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 58. Argentina New Molecular Entities (NME) Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 59. Colombia New Molecular Entities (NME) Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 60. Middle East and Africa New Molecular Entities (NME) Drugs Sales Market Share by Country (2021–2032)
Figure 61. Middle East and Africa New Molecular Entities (NME) Drugs Revenue Market Share by Country (2021–2032)
Figure 62. Turkey New Molecular Entities (NME) Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 63. Saudi Arabia New Molecular Entities (NME) Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 64. UAE New Molecular Entities (NME) Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 65. Global Sales Market Share of New Molecular Entities (NME) Drugs by Type (2021–2032)
Figure 66. Global Revenue Market Share of New Molecular Entities (NME) Drugs by Type (2021–2032)
Figure 67. Global New Molecular Entities (NME) Drugs Price (US$/Unit) by Type (2021–2032)
Figure 68. Global Sales Market Share of New Molecular Entities (NME) Drugs by Application (2021–2032)
Figure 69. Global Revenue Market Share of New Molecular Entities (NME) Drugs by Application (2021–2032)
Figure 70. Global New Molecular Entities (NME) Drugs Price (US$/Unit) by Application (2021–2032)
Figure 71. New Molecular Entities (NME) Drugs Value Chain
Figure 72. Channels of Distribution (Direct Vs Distribution)
Figure 73. Bottom-up and Top-down Approaches for This Report
Figure 74. Data Triangulation
Figure 75. Key Executives Interviewed
